Ikarian Capital, LLC Verona Pharma PLC Transaction History
Ikarian Capital, LLC
- $714 Million
- Q1 2025
A detailed history of Ikarian Capital, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Ikarian Capital, LLC holds 130,000 shares of VRNA stock, worth $9.81 Million. This represents 1.16% of its overall portfolio holdings.
Number of Shares
130,000
Previous 80,000
62.5%
Holding current value
$9.81 Million
Previous $3.72 Million
122.15%
% of portfolio
1.16%
Previous 0.61%
Shares
11 transactions
Others Institutions Holding VRNA
# of Institutions
291Shares Held
74.3MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$495 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$416 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$296 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$261 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$218 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $4.6B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...